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1. Introduction
Developments both in computer hardware and software allowed for storing, distributing, and
analyzing data obtained from biological experimentation, the very definition of bioinformatics.
From this standpoint, bioinformatics can be narrowly defined as a field at the crossroads of
biology and computer engineering, responsible for the storage, distribution, and analysis of
biological information.[1] The term of bioinformatics relatively refers to the formation and
advancement of algorithms, computational and statistical techniques, and theory to solve
formal and practical problems posed by or inspired from the management and analysis of
biological data.[2,3]
Since its emergence as an independent discipline in the 1980s, bioinformatics has been rapidly
developing, keeping up with the expansion of genome sequence data. Whereas it is safe to say
that 20 years ago, publishing computationally-derived results was a challenge and experi‐
mental observations were considered the only way of making progress[1]; after the famous
Clinton-Blair handshake for the completion of the human genome in April 2003 [4], headlines
such as ‘‘the laboratory rat is giving way to the computer mouse’’ arose.[5] The importance of
bioinformatics methods has further increased following the technological improvement of
large-scale gene expression analysis using DNA microarrays and proteomics experiments. Wet
experiments and the use of bioinformatics analyses go hand in hand in today’s biological and
clinical research.[6] Undeniably, it is almost inconceivable that a high-impact research
publication in biology does not contain some elements of computing.[1]
To date, the genome, transcriptome and proteome are investigated with large-scale and high-
throughput techniques to suggest treatment and predict outcomes. With the availability of
high-throughput sequencing in hypothesis driven science, various sequence-based techniques
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are originated, namely expressed sequence tags (ESTs)[7], serial analysis of gene expression
(SAGE)[8], massively parallel signature sequencing (MPSS)[9], the ‘HapMap’ project proceed‐
ing by means of individual SNPs (single nucleotide polymorphisms) to link specific genotypes
to diseases.[10,11] Aside from sequencing techniques, microarray technology is one of the
high-throughput techniques, possibly the most promising one. As for protein analysis
techniques, tissue arrays[12] and proteomics can be named.
On the one hand, microarrays are microscope slides or chips with immobilized probes, usually
cDNA (complementary DNA), BAC (bacterial artificial chromosome), or oligo probes.[13]
There are very large numbers of spots on an array, each containing a huge number of identical
DNA molecules. Two important applications of microarray technology are gene expression
monitoring and Single Nucleotide Polymorphisms (SNP) detection.[14] This technique is
widely applicable because less RNA is used to analyze thousands of genes. Despite its
increasing use around the world, microarray analysis has some limitations if used as a single
method for exploring tumor biology. An obvious weakness is that a microarray represents a
single snapshot of the patient.[15] But there are a large number of elements leading to disturbed
gene function[16], such as large and small deletions or single base substitutions, mutations
that affect promoter regions or splice-sites, as well as epigenetic silencing. Those factors may
influence the result but may go undetected as well, depending on the exact type of lesion as
well as its location with respect to the area hybridizing with the probe.[17] Furthermore,
differentially expressed genes do not necessarily translate into varying protein levels with
functional implications; so, it does not always show a correlation between the expression of a
gene and the amount of translated protein.[18] Also, compared to RT-PCR (reverse transcrip‐
tion polymerase chain reaction), microarray signals are less sensitive, accurate and not able to
resolve smaller differences in gene expression.[19] In addition to its comparative simplicity,
microarray technology requires better understanding of the limitations and careful attention
to experimental design and data analysis for meaningful results.
Bioinformatics applications are used in analysis of entire gene expression profiles to approach
the disease at genome level and pose new hypotheses regarding certain mechanisms including
but not limited to signaling pathways governing the process of formation, maintenance and
expansion of tumor.[20] Bioinformatics analyses can also be applied to miRNA, DNA copy-
number, SNPs, sequence, and methylation data[21] along with the field of medical sciences to
know the pathways for diagnosing which genomic changes could give rise to each known
inherited disease, i.e., identification of the gene causing disease, and also genetic therapies that
can reverse disease phenotype.[14] Different Browser and Databases has been developed to
analyze and process this huge quantity of data (Table 1.0 and Table 2.0).
Kept in mind that the discovery of complete protein classes is still in progress, e.g., the kinases
of the human genome[22], the classification of proteins with related structure and function[23]
will preserve its significance in the molecular dissection of human health and disease. In the
future, bioinformatics is expected to continue its fascinating interplay with the field of
genomics in cancer research, that is cancer bioinformatics and oncogenomics.[24]
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2. Bioinformatics in various cancers
Cancer is one of the prevalent diseases that bring about death worldwide. Given that Scientists
have sequenced the human genome[25], now it is time to use these genomic data, and the high-
throughput technology developed to generate them, to tackle major health problems such as
cancer.[24] Cancer molecular mechanisms are more successfully examined considering the
genes and proteins interaction and network. Bioinformatics tools are vital for acquiring a more
holistic view of cancer and analyzing the intricate data, speeding up the research process
including biomarker discovery. Moreover, cancer clinical bioinformatics is critical to reach
systems clinical medicine by combining clinical measurements and signs with human cancer
tissue-generated bioinformatics, understanding clinical symptoms and signs, disease devel‐
opment and progress, and therapeutic strategy.[26,27,28]
The leading cause of cancer death is lung cancer but still awaits reliable molecular markers.
Kim et al.[29] used multiple clinical samples and combined the bioinformatics analysis of the
public gene expression data with clinical validation to identify biomarker genes for non–small-
cell lung cancer, which shows poor prognosis and recurrence. They meta-analyzed the SAGE
and EST data and chose 20 genes for experimental validation through semiquantitative RT-
PCR. Then, applied quantitative RT-PCR to 7 genes (CBLC, CYP24A1, ALDH3A1, AKR1B10,
S100P, PLUNC, and LOC147166) identified as potential diagnostic markers, leading to 2 highly
probable novel biomarkers (CBLC and CYP24A1).
Liver cancer is the most common type, subsequent to lung cancer, responsible for cancer-
related deaths. Sawey et al.[30] performed a forward genetic screen, using a mouse hepatoblast
model and RNAi, guided by human hepatocellular carcinoma amplification data. They found
that the amplification led to the selective sensitivity to FGF19 inhibition. Hence, FGF19 is an
equally important driver gene of 11q13.3 amplicon as CCND1 in liver cancer, which means
11q13.3 amplification could be an effective biomarker for patients predicted to respond to anti-
FGF19 therapy.
In a recent study[31], an individualized bioinformatics analysis strategy was applied to
previously-established transcriptome data for clear cell renal cell carcinoma (ccRCC) to
identify and reposition 8 FDA-approved drugs with negative correlation and P-value <0.05 for
anticancer therapy. Authors demonstrated that pentamidine is effective against RCC cells in
culture, and slows tumor growth in a RCC xenograft mouse model so it might be a new
therapeutic agent to be combined with current standard-of-care regimens for patients with
metastatic RCC.
With regard to leukemia, diagnosis and subclassification is mostly based on the application of
various techniques like cytomorphology, cytogenetics, fluorescence in situ hybridization,
multiparameter flow cytometry, and PCR-based methods which are time-consuming and cost-
intensive, also require expertise in central reference laboratories. Therefore, microarray
analysis represents a novel promising method to be used as a diagnostic tool.[14] A key
determinant in the prognosis of chronic lymphocytic leukemia (CLL) is the mutational status
of the immunoglobulin heavy chain variable region (IGHV) genes.[32] For the correct delin‐
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eation of the mutational status, the patient’s leukemic cells and closest germline counterpart
should be compared. Unfortunately, public web-based databases are commonly used instead
of the patient’s germline DNA sequence from non-leukemic cells. Several of these reference
databases involve VBASE, GenBank/IgBLAST and the international ImMunoGeneTics
information systems that employ different software types, amount of natural IGHV polymor‐
phism and criteria used to map the complementarity determining regions and framework
regions. As a result, the correct interpretation of the IGHV mutational status in CLL may be
affected.[33]
Because of the heterogeneity of many tumors, it is a very challenging work to identify good
molecular targets. For instance, resistant subclones of overexpressed and mutated genes may
prevent them from being good molecular targets. Therefore, best target is a ‘red dot’ gene
whose mutation occurs early in oncogenesis and dysregulates a key pathway that drives tumor
growth in all of the subclones. Examples include mutations in the genes ABL, HER-2, KIT,
EGFR and probably BRAF, in chronic myelogenous leukemia, breast cancer, gastrointestinal
stromal tumors, non-small-cell lung cancer and melanoma, respectively. For efficacious
therapeutics; identification of red-dot targets, development of drugs that inhibit the red-dot
targets, and diagnostic classification of the related pathways are a must.[34]
3. Bioinformatics and breast cancer
Breast cancer occurs in both men and women, yet male breast cancer is less common. Although
a cure for each stage of breast cancer has not yet been found, identifying the genetic mutations
that cause the disease can play an important role and this is said by scientists to be like looking
for needles in a haystack, and after finding the needles or coding regions, they must find
disease-related sequences within them.[3,6] Bioinformatics sets the stage for searching 3 billion
base pairs to detect genetic defects.
Allinen et al. described the comprehensive gene expression profiles of each cell type composing
normal breast tissue and in situ and invasive breast carcinomas performing SAGE (serial
analysis of gene expression) and utilizing cell-type specific cell surface markers and magnetic
beads for the rapid sequential isolation. Their results suggest that considerable transcriptional
alterations happen in all cell populations while genetic changes were detected only in epithelial
cells among myoepithelial, endothelial and stromal cells, myofibroblasts and lymphocytes.[35]
To continue with another study, based upon a systematic Sanger sequencing analysis of 13,023
genes in 11 human breast cancers, individual tumors accumulate an average of approximately
90 point mutations in gene coding regions, but only a tiny number of these were recurrent and
were in significant genes of breast cancer, including p53 and PIK3CA. A much larger number
of the genes do not necessarily contribute to the carcinogenesis.[36] Considering the genomic
landscape of breast cancer, these more common mutations resemble “mountains” while the
vast majority of genes reflect “hills” that are infrequently mutated. We need to elucidate
mechanisms involved in the disease to understand the heterogeneity of human cancers and
utilize personal genomics for tumor diagnosis and new therapeutic strategies.[37]
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As widely accepted, early detection of breast cancer has an enormous impact on patient’s
survival. Seeing that genome-wide expression patterns of tumors mirror the biology of the
tumors, relating gene expression patterns to clinical outcomes sheds light on the biological
diversity of the tumors.[38] In the discovery of genes and pathways that are specifically
activated or inactivated during tumor progression, high throughput genome-wide array based
techniques like array comparative genomic hybridization (aCGH) and transcriptional profil‐
ing can be used.[13] A molecular classification of breast cancer, with more than five reprodu‐
cible subtypes (basal-like, ERBB2, normal-like, luminal A, luminal B) was defined through
gene expression profiling and microarray analysis.[38,39,17] In addition, performing the gene
set enrichment analysis (GSEA), a gene set linked to the growth factor (GF) signaling was
observed to be significantly enriched in the luminal B tumors.[40] Another study states that
multiple pathways were identified by mapping gene sets defined in Gene Ontology Biological
Process (GOBP) for estrogen receptor positive (ER+) or estrogen receptor negative (ER-); and
among them, in a separate set, pathways related to apoptosis and cell division or G-protein
coupled receptor signal transduction are associated with the metastatic capability of ER+or
ER-tumors, respectively.[41] Additionally, in a study, it is supported that breast cancer is
initiated with mutated stem cells/progenitors, also called “breast cancer stem cells” because
they are sufficient to sustain oncogenesis and tumor growth.[42] To identify genetic changes
in the progression of breast carcinoma, Yao et al. [43] used aCGH and SAGE combined for
ductal carcinoma in situ (DCIS), invasive breast carcinomas, and lymph node metastases. They
identified 49 minimal commonly amplified regions and reported that the overall frequency of
copy number alterations was more in invasive tumors than in DCIS, with several of them
present only in invasive cancer. In breast cancer, gene amplification happens recurrently on
some chromosomal locations (e.g. 1q, 8p12, 8q24, 11q13, 12p13, 12q13, 17q21-q23, 20q13)
[43,44], which points to the activation of some oncogenes at high frequency during the growth
of tumor. Amplification is a mechanism causing the gene expression constitutively enhanced
above the level of physiologically normal variation, so the significance of oncogene amplifi‐
cation in tumorigenesis had originated from expression profiling of tumor cells by oncogene
arrays.[45]
Bioinformatics is also crucial in the realm of pharmacogenomics. There became a need to
develop accurate tools for the effective treatment relying on biological characterization of each
patient’s tumor. Gene-expression profiling of tumors with DNA microarrays is a powerful tool
for pharmacogenomics targeting of treatments. Oncotype DX™ assay (Genomic Health) is a
good example, which was described for identifying the subset of node-negative estrogen-
receptor-positive breast cancer patients who do not require adjuvant chemotherapy.[46,34] A
recent research demonstrated that microarray analysis with qRT-PCR validation reveals
distinct pathways of resistance to bevacizumab (BEV) in xenograft models of human ER+breast
cancer, showing Follistatin (FST) and NOTCH as the top signaling pathways associated with
resistance in VEGF-driven tumors (P <0.05). According to the gene expression analysis, the
level of VEGF expression affects the response to BEV therapy and gene pathways.[47] Using
appropriate bioinformatics tools, such findings may elucidate the matter of resistance to drugs
for individual patients and provide a deeper understanding of treatments and risk factors,
opening the door from novel targets and disease-related biomarkers to right drugs.
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Last but not least, the effect of epigenetic changes on breast cancer etiology is beyond doubt.
In spite of quite a number of DNA methylation research manifesting diverse patterns including
tumor suppressor genes and oncogenes, only a small fraction of them connect the epigenome
data with the transcriptome. In a recent study by Minning and coworkers[48], DNA methyl‐
ation and gene expression profiling of primary breast tumor tissues and adjacent non-
cancerous breast tissues was carried out. They preferred MS-MLPA or MS-qPCR for validation
of results. The overlapping genes between DNA methylation and gene expression datasets
were further mapped to the KEGG database to identify the molecular pathways linking the
used genes together and supervised hierarchical clustering was used for data analysis. The
authors found that most of the overlapping genes belong to the focal adhesion and extracellular
matrix-receptor interaction that play important roles in breast carcinogenesis. The more gene
signature data is acquired by different studies, the better understanding of epigenetic regula‐
tion of gene expression and remedial intervention will be possible.
Advances in bioinformatics and its application are much possible by multidisciplinary teams
pursuing focused research. The sensitivity, specificity and combination of tools, methodolo‐
gies, and databases should be evaluated in a complete matter. On top of that, findings must
be confirmed with several molecular techniques before translation into clinical practice.
Database GroupDatabase Originator Web Adress
Nucleotide
Sequence
GenBank US National Center for Biotechnology
Information (NCBI)
www.ncbi.nlm.nih.gov/genbank
EMBL Europian Bioinformatics Institute www.ebi.ac.uk/
DDBJ National Institute of Genetic, Japan www.ddbj.nig.ac.jp/
dbEST www.ncbi.nlm.nih.gov/dbEST
Protein
Sequence
SWISS-PROT Swiss Institute of Bioinformatics, Geneva web.expasy.org/docs/swiss-
prot_guideline.html
European Bioinformatics Institute www.ebi.ac.uk/swissprot/
TREMBLE EBI (translation of coding sequences from the
EMBL database that have not yet been deposited
in SWISS-PROT)
www.ebi.ac.uk/tremble
UniProt Bioinformatics Institute (EMBL-EBI), Swiss
Institute of Bioinformatics (SIB) and the Protein
Information Resource (PIR).
www.uniprot.org
PIR US National Biomedical Research Foundation
(NBRF)
pir.georgetown.edu
Japan International Protein Information
Database (JIPID)
www.ddbj.nig.ac.jp
Munich Information Center for Protein
Sequences (MIPS)
mips.gsf.de
Table 1. Major electronic nucleotide and protein databases
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Genome Browser Originator Web Adress
Ensemble Wellcome Trust Sanger Institute/
Europian Bioinformatics Institute(EBI)
www.ensembl.org/
NCBI Map Viewer US National Center for Biotechnology
Information(NCBI)
www.ncbi.nlm.nih.gov/mapview/
UCSC genome browser Genome Bioinformatics Group of UC
Santa Cruz
http://genome.ucsc.edu/
Genomes Compilations
EBI Genomes Europian Bioinformatics Institute(EBI) www.ebi.ac.uk/genomes
GOLD Genomes Online Database www.genomesonline.org/
Table 2. Commonly used genom browser and databases
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